NASDAQ$SGMT

Sagimet Biosciences Inc-A · Q1 2023 earnings

Q1 2023 earnings · · Investor relations

Briefing

SGMT Q1 2023 — extraction skipped

Sagimet Biosciences Inc-A filed Form 8-K (accession 0001104659-24-061609) for Q1 2023, but headline financial numerics could not be extracted automatically: no headline numerics found by parser nor by Financial Datasets fallback. The row is marked as AI-processed so the queue advances; numerics will be filled by Financial Datasets on its next pass.

  • Form 8-K filed; press release body not parseable here.
  • Reason: no headline numerics found by parser nor by Financial Datasets fallback.
  • Numerics rely on the Financial Datasets fallback.

Headline financials

EPS (adj)

-$2.83K

Previous: -$0.39-717755.8%
Net Income

-$6.59M

Previous: -$8.74M+24.6%
Operating Income

-$6.77M

Previous: -$8.74M+22.6%
Stock-Based Comp

$767K

No prior period

Revenue & EPS history

Sagimet Biosciences · Revenue · Quarterly

$0

Q4 2026

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 10 quarterly earnings reports · overlaid with Q1 2023

Historical avgQ1 2023

-3.0%

Avg return

Earnings day

+0.6%

Avg return

5 days after

+17.0%

Avg return

30 days after

43%

6 / 14 earnings

Positive

+16.0%

Q4 2023

Best reaction

-21.4%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026-0.2%-10.2%-16.5%
Q3 2025-12.5%-11.3%-29.4%
Q1 2025+6.6%+7.1%+118.6%
Q4 2024+3.5%-7.0%-30.5%
Q3 2024-21.4%-26.7%-27.1%
Q2 2024+3.8%+6.0%+39.8%
Q1 2024+8.4%+8.2%-5.5%
Q1 2023+8.4%+8.2%-5.5%
Q4 2023+16.0%+20.2%-7.5%
Q3 2022-2.5%+14.5%+113.9%
Q3 2023-2.5%+14.5%+113.9%
Q2 2022-16.3%-5.1%-8.6%
Q2 2023-16.3%-5.1%-8.6%
Q4 2022-16.3%-5.1%-8.6%
Q1 2022
Q1 2021
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro